Impact of raloxifene or tamoxifen use on endometrial cancer risk: A population-based case-control study

Angela DeMichele, Andrea B. Troxel, Jesse A. Berlin, Anita L. Weber, Greta R. Bunin, Elene Turzo, Rita Schinnar, Desiree Burgh, Michelle Berlin, Stephen C. Rubin, Timothy R. Rebbeck, Brian L. Strom

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Purpose: Raloxifene reduces breast cancer risk in women with osteoporosis, and both tamoxifen and raloxifene prevent breast cancer in high-risk women. However, in vitro, raloxifene does not share the pro-estrogenic effects of tamoxifen on the endometrium. Randomized trials of these agents have provided limited information about endometrial cancer risk in the general population. We sought to compare endometrial cancer risks associated with raloxifene, tamoxifen, and nonusers of a selective estrogen receptor modulator (SERM) in the general population and characterize the endometrial tumors occurring in these groups. Methods: We performed a case-control study of white and African American women age 50 to 79 years in the Philadelphia area. Patients were diagnosed with endometrial cancer between July 1999 and June 2002. Controls were identified through random-digit dialing. Results: We analyzed 547 cases and 1,410 controls. Among cases, 3.3% had taken raloxifene; 6.2% had taken tamoxifen. Among controls, 6.6% had taken raloxifene; 2.4% had taken tamoxifen. After adjustment for other risk factors, the odds of endometrial cancer among raloxifene users was 50% that of nonusers (odds ratio [OR] = 0.50; 95% CI, 0.29 to 0.85), whereas tamoxifen users had three times the odds of developing endometrial cancer compared with raloxifene users (OR = 3.0; 95% CI, 1.3 to 6.9). Endometrial tumors in raloxifene users had a more favorable histologic profile and were predominantly International Federation of Gynecology and Obstetrics stage I and low grade. Conclusion: Raloxifene users had significantly lower odds of endometrial cancer compared with both tamoxifen users and SERM nonusers, suggesting a role for raloxifene in endometrial cancer prevention and individualization of SERM therapy.

Original languageEnglish (US)
Pages (from-to)4151-4159
Number of pages9
JournalJournal of Clinical Oncology
Volume26
Issue number25
DOIs
StatePublished - Sep 18 2008

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

DeMichele, A., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., Schinnar, R., Burgh, D., Berlin, M., Rubin, S. C., Rebbeck, T. R., & Strom, B. L. (2008). Impact of raloxifene or tamoxifen use on endometrial cancer risk: A population-based case-control study. Journal of Clinical Oncology, 26(25), 4151-4159. https://doi.org/10.1200/JCO.2007.14.0921